Indium (111In) capromab pendetide

{{DISPLAYTITLE:Indium (¹¹¹In) capromab pendetide}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458271478

| image =

| drug_name = Indium (¹¹¹In) capromab pendetide

| type = mab

| mab_type = mab

| source = o

| target = Glutamate carboxypeptidase II

| tradename = Prostascint

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 151763-64-3

| CAS_supplemental = (capromab)
{{CAS|148805-91-8}} (pendetide)

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 03MZ53X1YS

| ATC_prefix = V09

| ATC_suffix = IB04

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201579

| chemical_formula =

| molecular_weight =

}}

Indium (¹¹¹In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.{{cite journal | vauthors = Manyak MJ | title = Indium-111 capromab pendetide in the management of recurrent prostate cancer | journal = Expert Review of Anticancer Therapy | volume = 8 | issue = 2 | pages = 175–81 | date = February 2008 | pmid = 18279057 | doi = 10.1586/14737140.8.2.175 | s2cid = 30587577 }} Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[https://web.archive.org/web/20040627024748/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list67.pdf WHO Drug Information] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).

Early trials with yttrium (⁹⁰Y) capromab pendetide were also conducted.{{cite journal | vauthors = Kahn D, Austin JC, Maguire RT, Miller SJ, Gerstbrein J, Williams RD | title = A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy | journal = Cancer Biotherapy & Radiopharmaceuticals | volume = 14 | issue = 2 | pages = 99–111 | date = April 1999 | pmid = 10850293 | doi = 10.1089/cbr.1999.14.99 }}